Alumis Inc (ALMS)

$25.06 -0.32 (-1.26%)
Market Cap 2.65B
Revenue (ttm) 0.00
Net Income (ttm) -294.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,029,900
Avg Vol 1,943,312
Day's Range N/A - N/A
Shares Out 104.39M
Stochastic %K 24%
Beta -2.15
Analysts Strong Sell
Price Target $38.80

Company Profile

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to ad...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 231 6625
Address:
280 East Grand Avenue, South San Francisco, United States
IN0V8
IN0V8 Mar. 20 at 3:36 PM
$ALMS Morgan Stanley raises target price to $38 from $33
0 · Reply
erevnon
erevnon Mar. 20 at 2:43 PM
Morgan Stanley maintains Alumis $ALMS at Overweight and raises the price target from $33 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
erevnon
erevnon Mar. 20 at 12:22 PM
Chardan Capital maintains Alumis $ALMS at Buy and raises the price target from $37 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Quantumup
Quantumup Mar. 18 at 2:40 PM
Truist reiterated $PTGX Buy; $110, $JNJ $ABVX $ALMS ABBV $TAK Truist said:::This morning, Protagonist (PTGX, Buy) and Johnson & Johnson (JNJ, NR) reported FDA approval of Icotyde (icotrokinra) in 12+ year old moderate to severe plaque psoriasis (PsO), marking Protagonist's official transition to a commercial company. We see strong differentiation as the first oral therapy with biologic-like efficacy in a TAM with ~8M patients, as per JNJ. We model $730M peak revenue to PTGX in royalties vs $560M consensus and note partner JNJ (JNJ, NR) estimates ico to present a~$5-10B market opportunity. With priority review for rusfertide (launch expected 2H26), we think this sets PTGX up to continue to deliver pipeline progress with strong cash position. Reiterate Buy.
1 · Reply
mlete21
mlete21 Mar. 16 at 2:39 PM
$ALMS consolidating!
0 · Reply
mlete21
mlete21 Mar. 16 at 2:38 PM
$ALMS consolidating
0 · Reply
JD101
JD101 Mar. 15 at 5:41 PM
$RCKT intresting that $ALMS also fell dramatically into the PDUFA
0 · Reply
aletz
aletz Mar. 13 at 10:14 AM
$ALMS https://www.biostockinfo.com/biotech-catalyst-ai-scanner-march-wk3/ ALMS, #2 pick from the AI Catalyst Scanner of March 3rd week, is worth checking out. For more catalyst-based biotech investment ideas, visit the link provided.
0 · Reply
IN0V8
IN0V8 Mar. 12 at 10:27 PM
$ALMS sold a small position at $25 to trim my exposure.
0 · Reply
pregn4nt
pregn4nt Mar. 12 at 7:33 AM
$ALMS https://meyka.com/blog/raymond-james-starts-alms-alumis-inc-common-stock-at-strong-buy-mar-2026-1203/
0 · Reply
Latest News on ALMS
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Mar 19, 2026, 4:05 PM EDT - 2 days ago

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

Mar 18, 2026, 8:00 AM EDT - 3 days ago

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

Alumis to Present at the Leerink Partners Global Healthcare Conference

Mar 2, 2026, 8:05 AM EST - 19 days ago

Alumis to Present at the Leerink Partners Global Healthcare Conference

Alumis to Participate in Upcoming February Investor Conferences

Feb 5, 2026, 8:05 AM EST - 6 weeks ago

Alumis to Participate in Upcoming February Investor Conferences

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 9, 2026, 4:05 PM EST - 2 months ago

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Alumis Announces Pricing of Upsized Public Offering of Common Stock

Jan 7, 2026, 10:52 PM EST - 2 months ago

Alumis Announces Pricing of Upsized Public Offering of Common Stock

Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise

Jan 7, 2026, 11:22 AM EST - 2 months ago

Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise

Alumis Announces Proposed Public Offering of Common Stock

Jan 6, 2026, 4:12 PM EST - 2 months ago

Alumis Announces Proposed Public Offering of Common Stock

Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars

Jan 6, 2026, 10:47 AM EST - 2 months ago

Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars

Alumis skin disease drug meets main goal of two late-stage trials

Jan 6, 2026, 7:07 AM EST - 2 months ago

Alumis skin disease drug meets main goal of two late-stage trials

Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Jan 6, 2026, 7:00 AM EST - 2 months ago

Alumis' Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Jan 5, 2026, 5:00 PM EST - 2 months ago

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 13, 2025, 4:15 PM EST - 4 months ago

Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Alumis to Participate in Upcoming November Investor Conferences

Nov 4, 2025, 8:00 AM EST - 4 months ago

Alumis to Participate in Upcoming November Investor Conferences

Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript

Sep 17, 2025, 4:53 AM EDT - 6 months ago

Alumis Inc. (ALMS) Presents at Stifel Virtual Immunology and Inflammation Forum Transcript

Alumis to Participate in Upcoming September Investor Conferences

Aug 29, 2025, 7:00 AM EDT - 7 months ago

Alumis to Participate in Upcoming September Investor Conferences

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 7 months ago

Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Jul 24, 2025, 7:30 AM EDT - 8 months ago

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Jul 14, 2025, 4:05 PM EDT - 8 months ago

Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary

Alumis to Present at the Jefferies Global Healthcare Investor Conference

May 29, 2025, 4:15 PM EDT - 10 months ago

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

May 29, 2025, 7:55 AM EDT - 10 months ago

Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis

Alumis Completes Merger with ACELYRIN

May 21, 2025, 9:10 AM EDT - 10 months ago

Alumis Completes Merger with ACELYRIN

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

May 14, 2025, 4:05 PM EDT - 11 months ago

Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Stockholders Approve Merger with ACELYRIN

May 13, 2025, 1:00 PM EDT - 11 months ago

Alumis Stockholders Approve Merger with ACELYRIN

Alumis and ACELYRIN Announce Amended Merger Agreement

Apr 21, 2025, 6:30 AM EDT - 11 months ago

Alumis and ACELYRIN Announce Amended Merger Agreement

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

Apr 16, 2025, 5:31 PM EDT - 1 year ago

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

SLRN

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

Apr 14, 2025, 10:02 AM EDT - 1 year ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO AMRN CCO ECX HZO NUTX

Top 3 Health Care Stocks That May Crash In Q2

Apr 7, 2025, 11:23 AM EDT - 1 year ago

Top 3 Health Care Stocks That May Crash In Q2

CMRX DERM

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Apr 4, 2025, 4:34 PM EDT - 1 year ago

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Mar 25, 2025, 2:30 AM EDT - 1 year ago

Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Mar 19, 2025, 4:05 PM EDT - 1 year ago

Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Alumis to Present at Leerink's 2025 Global Healthcare Conference

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Mar 8, 2025, 9:00 AM EST - 1 year ago

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

Mar 4, 2025, 9:01 AM EST - 1 year ago

Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Mar 4, 2025, 9:00 AM EST - 1 year ago

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

SLRN

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Feb 28, 2025, 9:08 AM EST - 1 year ago

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Feb 27, 2025, 4:15 PM EST - 1 year ago

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 10, 2025, 4:45 PM EST - 1 year ago

Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

Feb 7, 2025, 3:22 PM EST - 1 year ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC.

SLRN

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Feb 6, 2025, 4:15 PM EST - 1 year ago

Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

Alumis Strengthens Leadership Team with Key Appointments

Jan 28, 2025, 8:00 AM EST - 1 year ago

Alumis Strengthens Leadership Team with Key Appointments

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Nov 13, 2024, 4:05 PM EST - 1 year ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

Oct 17, 2024, 2:32 PM EDT - 1 year ago

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

BMY

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Oct 4, 2024, 2:00 AM EDT - 1 year ago

Alumis: Could This Broken Immunology IPO Become The Next Amgen?

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Sep 27, 2024, 9:00 AM EDT - 1 year ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Sep 16, 2024, 4:32 PM EDT - 1 year ago

Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Jul 29, 2024, 8:00 AM EDT - 1 year ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

Jul 24, 2024, 3:18 PM EDT - 1 year ago

Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

IN0V8
IN0V8 Mar. 20 at 3:36 PM
$ALMS Morgan Stanley raises target price to $38 from $33
0 · Reply
erevnon
erevnon Mar. 20 at 2:43 PM
Morgan Stanley maintains Alumis $ALMS at Overweight and raises the price target from $33 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
erevnon
erevnon Mar. 20 at 12:22 PM
Chardan Capital maintains Alumis $ALMS at Buy and raises the price target from $37 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Quantumup
Quantumup Mar. 18 at 2:40 PM
Truist reiterated $PTGX Buy; $110, $JNJ $ABVX $ALMS ABBV $TAK Truist said:::This morning, Protagonist (PTGX, Buy) and Johnson & Johnson (JNJ, NR) reported FDA approval of Icotyde (icotrokinra) in 12+ year old moderate to severe plaque psoriasis (PsO), marking Protagonist's official transition to a commercial company. We see strong differentiation as the first oral therapy with biologic-like efficacy in a TAM with ~8M patients, as per JNJ. We model $730M peak revenue to PTGX in royalties vs $560M consensus and note partner JNJ (JNJ, NR) estimates ico to present a~$5-10B market opportunity. With priority review for rusfertide (launch expected 2H26), we think this sets PTGX up to continue to deliver pipeline progress with strong cash position. Reiterate Buy.
1 · Reply
mlete21
mlete21 Mar. 16 at 2:39 PM
$ALMS consolidating!
0 · Reply
mlete21
mlete21 Mar. 16 at 2:38 PM
$ALMS consolidating
0 · Reply
JD101
JD101 Mar. 15 at 5:41 PM
$RCKT intresting that $ALMS also fell dramatically into the PDUFA
0 · Reply
aletz
aletz Mar. 13 at 10:14 AM
$ALMS https://www.biostockinfo.com/biotech-catalyst-ai-scanner-march-wk3/ ALMS, #2 pick from the AI Catalyst Scanner of March 3rd week, is worth checking out. For more catalyst-based biotech investment ideas, visit the link provided.
0 · Reply
IN0V8
IN0V8 Mar. 12 at 10:27 PM
$ALMS sold a small position at $25 to trim my exposure.
0 · Reply
pregn4nt
pregn4nt Mar. 12 at 7:33 AM
$ALMS https://meyka.com/blog/raymond-james-starts-alms-alumis-inc-common-stock-at-strong-buy-mar-2026-1203/
0 · Reply
Quantumup
Quantumup Mar. 10 at 8:15 PM
Raymond James🏁 $ALMS $JNJ - $PTGX $BMY Raymond James Said—Initiating coverage of ALMS shares with a Strong Buy rating, $46 price target in that we think lead asset envudeucitinib (envu) — a next generation, more potent TYK2 inhibitor — is well positioned to take meaningful share in the massive and growing market for non-biologic options in moderate-to-severe plaque psoriasis (PsO). As we detail herein, while the market seems to assume Johnson & Johnson's (JNJ) icotrokinra (oral IL-23 inhibitor) is the heir apparent in this field, we think envu's emerging profile is likely to offer enough differentiation to compete head-to-head, while also changing the narrative around TYK2 inhibition after a disappointing launch for Bristol-Myers' (BMY) Sotyktu. We would be buyers in front of full data at this year's AAD (March 27-31) and for what we anticipate will be a launch that meaningfully exceeds investor expectations.
0 · Reply
outlawinvestor1
outlawinvestor1 Mar. 9 at 8:22 PM
$ALMS ceo let it slip at leerink meeting that envu ph3 data was given a late-breaker slot at aad 2026.
0 · Reply
BPler
BPler Mar. 4 at 6:24 PM
$CRVO -50% in 3 months, despite all positive news, is not dilution fear, looks more like a weird combination of swing traders, instutional buy-in with lending shares (over 7% fees) and bleeding out on constant short pressure. And dilution is not the wanted solution for management, if they bet on that, they would have done this months ago for a higher price. Like $ALMS or other biotech you usually try to dilute on good news as your fair company value would go up. Only incompetent management does dilute on bad news as a result on bad management. I understand any negative sentiment here from an emotional point, but I just don't see the overwhelming evidence for a bear case which says this company is worth so less as the market cap is today. Even fucking $MS made them a benefical owner, they have like 1000% better analysis insights as my 2cents.
1 · Reply
Stackdoe101
Stackdoe101 Mar. 2 at 6:11 AM
$ALMS 🙃✨️🚀📈
0 · Reply
Quantumup
Quantumup Feb. 26 at 4:07 PM
Evercore ISI reiterated $VRDN Outperform-$45 and added to its TAP Outperform List. $AMGN $IMVT - ROIV $ALMS NVS $TRML Jefferies⬆️the PT to $45 from $44 and reiterated at a Buy rating. Here's what Evercore ISI and Jefferies had to say: https://x.com/Quantumup1/status/2027052196878041525?s=20
0 · Reply
erevnon
erevnon Feb. 25 at 11:39 AM
Stifel initiates coverage on Alumis $ALMS at Buy rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Quantumup
Quantumup Feb. 24 at 9:24 PM
Stifel🏁 $ALMS and said, We are initiating coverage with a Buy Rating and $44 Target Price on Alumis Inc. (ALMS). $TAK $BMY $JNJ - $PTGX NVS ABBV Stifel added, Our positive thesis on the stock is predicated on our view that next-generation TYK2s with the ability to achieve full target coverage have the potential to grow into an important oral class with the benefit of no Boxed Warning. To that end, topline data in Psoriasis from ALMS' Envudeucitinib provides support for the target coverage thesis with data that looks superior to both Zasocitinib and Sotyktu—more details likely to come at AAD (3/27-3/31). Ultimately, success here derisks broader development not only in SLE (data 3Q26) but also in the plethora of other diseases where there's clear support for the TYK2 target/coverage hypothesis. Looking ahead, with an NDA filing on track in psoriasis in 2H26, we see a path towards a strategic transaction to support the launch and expansion of the TYK2+ pipeline.
0 · Reply
teksviler
teksviler Feb. 24 at 3:34 PM
$LAB Adding right now. $ALMS $BE $THM USAR Some of my a bit risky plays.
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 23 at 1:25 PM
$ALMS Current Stock Price: $27.96 Contracts to trade: $28.0 ALMS Mar 20 2026 Call Entry: $2.83 Exit: $3.81 ROI: 34% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 1:17 AM
$ALMS RSI: 66.94, MACD: 2.0870 Vol: 1.07, MA20: 26.56, MA50: 19.85 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Brianum2011
Brianum2011 Feb. 21 at 12:39 AM
$SLS Just added ah now. Let’s hope for a big move next week just like immunitybio lately My other top biotechs I’m holding: $IBRX $PRAX $ALMS $TERN Have a great weekend!
3 · Reply